CL2007000529A1 - Antigeno vacunal quimerico contra el virus de la peste porcina clasica, vppc, que contiene el segmento extracelular de la glicoproteina e2 de la envoltura viral del vppc y una proteina estimuladora del sistema inmune cd154; composicion que lo comprende. - Google Patents

Antigeno vacunal quimerico contra el virus de la peste porcina clasica, vppc, que contiene el segmento extracelular de la glicoproteina e2 de la envoltura viral del vppc y una proteina estimuladora del sistema inmune cd154; composicion que lo comprende.

Info

Publication number
CL2007000529A1
CL2007000529A1 CL2007000529A CL2007000529A CL2007000529A1 CL 2007000529 A1 CL2007000529 A1 CL 2007000529A1 CL 2007000529 A CL2007000529 A CL 2007000529A CL 2007000529 A CL2007000529 A CL 2007000529A CL 2007000529 A1 CL2007000529 A1 CL 2007000529A1
Authority
CL
Chile
Prior art keywords
vppc
glycoprotein
composition
immune system
understands
Prior art date
Application number
CL2007000529A
Other languages
English (en)
Inventor
Alonso Jorge Roberto Toledo
Ramos Oliberto Sanchez
Valle Maritza Isidra Barrera
Baile Nancy Elena Figueroa
Carratala Yanet Prieto
Molto Maria Pilar Rodriguez
Lepoureau Maria Teresa Frias
Nordelo Carlos Guillermo Borroto
Original Assignee
Ct Ingenieria Genetica Biotech
Ct Nac De Sanidad Agropecuaria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech, Ct Nac De Sanidad Agropecuaria filed Critical Ct Ingenieria Genetica Biotech
Publication of CL2007000529A1 publication Critical patent/CL2007000529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Antígeno vacunal quimérico contra el virus de la peste porcina clásica, vppc, que contiene el segmento extracelular de la glicoproteína e2 de la envoltura viral del vppc y una proteína estimuladora del sistema inmune; y composición que lo comprende.
CL2007000529A 2006-02-28 2007-02-27 Antigeno vacunal quimerico contra el virus de la peste porcina clasica, vppc, que contiene el segmento extracelular de la glicoproteina e2 de la envoltura viral del vppc y una proteina estimuladora del sistema inmune cd154; composicion que lo comprende. CL2007000529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060052A CU23544A1 (es) 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la peste porcina clásica

Publications (1)

Publication Number Publication Date
CL2007000529A1 true CL2007000529A1 (es) 2008-01-18

Family

ID=38279009

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007000529A CL2007000529A1 (es) 2006-02-28 2007-02-27 Antigeno vacunal quimerico contra el virus de la peste porcina clasica, vppc, que contiene el segmento extracelular de la glicoproteina e2 de la envoltura viral del vppc y una proteina estimuladora del sistema inmune cd154; composicion que lo comprende.

Country Status (17)

Country Link
US (1) US8409562B2 (es)
EP (1) EP1994943B1 (es)
JP (1) JP5190383B2 (es)
KR (1) KR101506979B1 (es)
CN (2) CN105214081A (es)
AR (1) AR059648A1 (es)
AT (1) ATE490782T1 (es)
BR (1) BRPI0708354B1 (es)
CA (1) CA2638830C (es)
CL (1) CL2007000529A1 (es)
CU (1) CU23544A1 (es)
DE (1) DE602007011042D1 (es)
ES (1) ES2357563T3 (es)
HK (1) HK1219052A1 (es)
MX (1) MX2008011144A (es)
RU (1) RU2406534C2 (es)
WO (1) WO2007098717A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10307475B2 (en) 2009-03-27 2019-06-04 Academia Sinica Methods and compositions for immunization against virus

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362416B (en) * 2008-07-31 2012-04-21 Mao Xing Biolog Technology Co Ltd Yeast expressed classical swine fever virus glycoprotein e2 and use thereof
RU2727847C2 (ru) * 2016-05-12 2020-07-24 Биоэппликейшнз Инк. Растительная композиция для вакцинации против чумы свиней и способ ее приготовления
PH12021552552A1 (en) * 2019-04-25 2022-06-20 Agricultural Tech Res Inst Recombinant protein for preventing swine fever virus infection and composition and cell containing the same
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
CU20210070A7 (es) * 2021-08-20 2023-03-07 Ct Ingenieria Genetica Biotecnologia Antígenos quiméricos para el control de coronavirus y composiciones que los comprenden
CN114835822B (zh) * 2022-04-22 2022-11-04 浙江洪晟生物科技股份有限公司 猪瘟病毒的多聚体疫苗及其制备方法
CN118126140B (zh) * 2023-04-10 2026-03-27 浙江省农业科学院 一种表达猪瘟病毒e2蛋白的重组伪狂犬病毒株及应用
WO2024235368A1 (es) * 2023-05-18 2024-11-21 Centro De Ingeniería Genética Y Biotecnología Composicion vacunal contra el virus de la peste porcina africana
CU20230025A7 (es) * 2023-05-18 2024-12-09 Ct Ingenieria Genetica Biotecnologia Formulación para la inmunización de cerdos por la vía oral
CN118530369A (zh) * 2024-01-19 2024-08-23 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种猪瘟病毒e2-il28b融合蛋白及其作为抗原在制备猪瘟亚单位疫苗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
ZA901719B (en) 1989-03-19 1991-01-30 Akzo Nv Hog cholera virus vaccine and diagnostics
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
FR2804028B1 (fr) 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
WO2001083737A2 (en) 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
RU2183972C2 (ru) 2000-07-13 2002-06-27 ВНИИ ветеринарной вирусологии и микробиологии Способ получения высокоактивной специфической к вирусу классической чумы свиней сыворотки крови свиней
CN1338309A (zh) 2000-08-10 2002-03-06 清华大学 一种合成肽猪瘟疫苗及其制备方法
RU2182495C1 (ru) 2001-05-03 2002-05-20 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Вирусвакцина против классической чумы свиней
US20040096457A1 (en) * 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
CU23102A1 (es) * 2002-10-21 2005-12-20 Ct Ingenieria Genetica Biotech Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos
US7183384B2 (en) * 2003-03-06 2007-02-27 A & G Pharmaceutical, Inc. Monoclonal antibody 7H11 reactive with human cancer
EP1522585A1 (en) * 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10307475B2 (en) 2009-03-27 2019-06-04 Academia Sinica Methods and compositions for immunization against virus
US11672853B2 (en) 2009-03-27 2023-06-13 Academia Sinica Methods and compositions for immunization against virus

Also Published As

Publication number Publication date
CA2638830C (en) 2015-04-14
BRPI0708354A2 (pt) 2011-05-24
DE602007011042D1 (de) 2011-01-20
CN105214081A (zh) 2016-01-06
JP5190383B2 (ja) 2013-04-24
KR101506979B1 (ko) 2015-03-30
WO2007098717A2 (es) 2007-09-07
RU2406534C2 (ru) 2010-12-20
US20090304633A1 (en) 2009-12-10
EP1994943B1 (en) 2010-12-08
EP1994943A2 (en) 2008-11-26
US8409562B2 (en) 2013-04-02
HK1219052A1 (zh) 2017-03-24
CU23544A1 (es) 2010-06-17
WO2007098717A3 (es) 2007-11-01
ATE490782T1 (de) 2010-12-15
KR20080111023A (ko) 2008-12-22
RU2008138536A (ru) 2010-04-10
CN101426525A (zh) 2009-05-06
MX2008011144A (es) 2009-01-26
AR059648A1 (es) 2008-04-16
BRPI0708354B1 (pt) 2016-04-19
JP2009528304A (ja) 2009-08-06
ES2357563T3 (es) 2011-04-27
CA2638830A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
CL2007000529A1 (es) Antigeno vacunal quimerico contra el virus de la peste porcina clasica, vppc, que contiene el segmento extracelular de la glicoproteina e2 de la envoltura viral del vppc y una proteina estimuladora del sistema inmune cd154; composicion que lo comprende.
CL2007000526A1 (es) Antigeno vacunal quimerico contra el virus de la influenza aviar, ia, que contiene el segmento extracelular de la hemaglutinina de la envoltura del virus de ia y el segmento extracelular de la proteina cd154; y composicion que lo comprende.
CL2019002036A1 (es) Anticuerpo contra bcma y su uso.
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
CR20160041A (es) Proteína de fusión terapéutica
CY1120328T1 (el) Συνθεση εμβολιου περιεχουσα συνθετικο ανοσοενισχυτικο
CY1121535T1 (el) Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων
CY1115932T1 (el) Σκευασμα αντισωματος
ATE552846T1 (de) Verbesserter grippeimpfstoff
CO6480978A2 (es) Antigenos de virus de sincicio respiratorio recombinantes
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
MA39803A (fr) Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation
TW200732476A (en) Functional influenza virus like particles (VLPs)
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
CO2019011640A2 (es) Métodos y composiciones para la reducción de la inmunogenicidad
ES2562774T3 (es) Vacunas para la gripe basadas en el virus del mosaico de la papaya
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
CL2012003094A1 (es) Anticuerpo bivalente aislado o fragmento bivalente del mismo, que actua sobre lrp6 potenciando una señal wnt al agrupar uno o mas receptores lrp6 en presencia de una proteina de union de lrp6; acido nucleico que lo codifica; vector que comprende dicho acido nucleico; composicion farmaceutica que comprende un anticuerpo multivalente anti-lrp6; y su uso para tratar cancer.
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
EP3956438A4 (en) CSFV SUBUNITE VACCINE
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
AR101814A1 (es) Partícula de tipo virus flavivirus
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CL2013001861A1 (es) Proteina recombinante que comprende el dominio extracelular derivado de la proteina robo1 o una parte del mismo, un conector y un dominio fc de inmunoglobulina; y su uso para tratar cancer.
MX2019010895A (es) Formulacion liquida de anticuerpo anti-tnf alfa.